Eupatilin

Name: Eupatilin
Brand: Phytopurify
Rating: 5 (1 reviews)

Catalogue No.： BP0576

CAS NO.: 22368-21-4

Purity: 98%

Brand: Phytopurify

Botanical Source: Artemisia argyi Levl.et Vant.

Eupatilin has anti-inflammatory, and anti-tumor properties, it inhibits the MKN-1 gastric cancer cell proliferation via activation of caspase-3 and the metastatic potential of gastric cancer cells via down-regulation of NF-κB activity followed by reduction of pro-inflammatory cytokine-mediated MMPs expressions. Eupatilin inhibits the signalling of MAPK, IKK, NF-κB and eotaxin-1 in bronchial epithelial cells, leading to inhibition of eosinophil migration. Eupatilin is also a promising therapeutic agent against acute ischemia-induced renal damage, it significantly increases the levels of heat shock protein 70 and B-cell lymphoma protein, and it attenuates inducible nitric oxide synthase, Bcl-2-associated X protein, and caspase-3 levels. Eupatilin is a trimethoxyflavone that is flavone substituted by hydroxy groups at C-5 and C-7 and methoxy groups at C-6, C-3' and C-4' respectively. Isolated from Citrus reticulata and Salvia tomentosa, it exhibits anti-inflammatory, anti-ulcer and antineoplastic activities. It has a role as a metabolite, an antineoplastic agent, an anti-ulcer drug, an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor and an anti-inflammatory agent. It is a trimethoxyflavone and a dihydroxyflavone.

View larger image

Catalog No	Package	Original Price	Price	Inventory	Quantity	Operating
BP0576-20mg	20mg	Sign in	Sign in
BP0576-100mg	100mg	Sign in	Sign in

Contacts：400-829-7929，028-82633860，82633397，82633165

After logging in, view the price and place an order

Consult Collect

Related diseases

Inflammatory Bowel Disease Non-alcoholic fatty liver disease Antitumor Gastric ulcer Allergic Asthma

Related targets

Inflammatory Bowel Disease STAT3 AMPK ALOX5 CASP1 MAPK1 TNF NOS2 PTGS2 NFKB1 IL1B SOD1 HMOX1 TGFB1 VEGFA PPARA TJP1

Non-alcoholic fatty liver disease STAT3 AMPK ALOX5 CASP1 MAPK1 ESR1 TNF NOS2 SREBF1 PTGS2 NFKB1 IL1B SOD1 HMOX1 TGFB1 FASN CPT1A PPARA

Antitumor STAT3 MAPK1 ESR1 PGR PTGS2 NFKB1 BRCA1 HER2 CCND1 VEGFA

Gastric ulcer PTGS1 TNF NOS2 PTGS2 NFKB1 IL1B SOD1 CAT HMOX1 VEGFA MUC5AC

Allergic Asthma STAT3 ALOX5 TNF NOS2 PTGS2 HDAC2 NFKB1 IL4 IL5 IL13 FCER1A MUC5AC TSLP

Product description Related Products Prediction Parameters Reference Literature

Product name: Eupatilin
Synonym name:
Catalogue No.: BP0576
Cas No.: 22368-21-4
Formula: C₁₈H₁₆O₇
Mol Weight: 344.319
Botanical Source: Eupatorium semiserratum, Tanacetum vulgare (tansy) and Liatris punctata
Physical Description: Yellow powder
Type of Compound: Flavonoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams, up to kilograms
Inquire for bulk scale.

Descriptions:
Eupatilinthe has anti-proliferative effect in MCF10A- ras cells, is associated with its blockade of cell cycle progression which appears to be attributable in part to inhibition of ERK1/2 activation.[1]
Eupatilin attenuates bile acid-induced hepatocyte apoptosis by suppressing bile acid-induced kinase activation, it might be therapeutically efficacious in a variety of human liver diseases associated with cholestasis.[2]
Eupatilin and jaceosidin have effects on cytochrome p450 enzyme activities in human liver microsomes, have potential pharmacokinetic drug interactions in vivo due to inhibition of CYP1A2 and CYP2C9.[3]
Eupatilin is a potent anti-atherogenic agent that inhibits PDGF-BB-induced proliferation and migration in HASMCs as well as aortic sprouting, which is likely mediated through the attenuation of PI3K, MKK3/6, and MKK4 activation.[4]
Eupatilin suppresses oxidative damage and reciprocally enhances extracellular matrix production in articular chondrocytes, making eupatilin a promising therapeutic option for the treatment.[5]
Eupatilin improves the acute hepatic IRI by reducing inflammation and apoptosis, it is a promising therapeutic agent against acute IR-induced hepatic damage.[6]
Eupatilin protects against tumor necrosis factor-α-mediated inflammation inhuman umbilical vein endothelial cells.[7]
Eupatilin induces Sestrin2-dependent autophagy to prevent oxidative stress.[8]

References:
[1] Kim D H, Na H K, Oh T Y, et al. Biochem Pharmacol, 2004, 68(6):1081-7.
[2] Su C P, Yoon J H, Kim W, et al. J Gastroenterol, 2006, 41(8):772-8.
[3] Ji H Y, Kim S Y, Kim D K, et al. Molecules, 2010, 15(9):6466-75.
[4] Son J E, Lee E, Seo S G, et al. Planta Med, 2013, 79(12):1009-16.
[5] Jeong J H, Moon S J, Jhun J Y, et al. Plos One, 2015, 10(6):e0130882.
[6] Lee H M, Jang H J, Kim S S, et al. Transpl P, 2016, 48(4):1226-33.
[7] Yu K, Li X M, Xu X L, et al. Int J Clin Exp Med, 2016, 8(12):22191-7.
[8] Jegal K H, Ko H L, Sang M P, et al. Apoptosis, 2016, 21(5):1-15.
[9] Zhou Q, Sun L L, Jiang B, et al. China Pharm, 2013, 24(47):4464-6.